Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May
April 08, 2020 06:00 ET
|
Novavax, Inc.
NVX-CoV2373 identified as SARS-CoV-2 candidate for Phase 1 clinical trialIn preclinical studies, NVX-CoV2373 demonstrated high immunogenicity and stimulated high levels of neutralizing...
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
March 24, 2020 06:00 ET
|
Novavax, Inc.
Trial also achieves statistical significance in key secondary endpointsNovavax to submit a U.S. BLA under FDA’s accelerated approval pathwayCompany to host investor conference call today at 8:30 a.m....
Novavax Reports Fourth Quarter and Full Year 2019 Financial Results
March 11, 2020 16:17 ET
|
Novavax, Inc.
NanoFlu top-line data from Phase 3 clinical trial expected by the end of this monthNovavax awarded CEPI funding to support COVID-19 vaccine programCOVID-19 Phase 1 clinical trial expected to initiate...
Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate
March 11, 2020 10:45 ET
|
Novavax, Inc.
Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford UniversityPhase 2b clinical efficacy study of experimental malaria...
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
March 10, 2020 05:30 ET
|
Novavax, Inc.
CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trialsPhase 1...
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020
March 05, 2020 16:05 ET
|
Novavax, Inc.
GAITHERSBURG, Md., March 05, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax Advances Development of Novel COVID-19 Vaccine
February 26, 2020 09:27 ET
|
Novavax, Inc.
Vaccine candidate derived from coronavirus spike (S) proteinMatrix-M™ adjuvant expected to boost immune responsesPhase 1 clinical trial planned for late spring GAITHERSBURG, Md., Feb. 26, 2020 ...
Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity
February 25, 2020 16:05 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax Granted Fast Track Designation for NanoFlu in Older Adults
January 15, 2020 08:30 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 09, 2020 16:05 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...